The University of Houston has transformed its Energy Research Park into the Technology Bridge to better connect research-based startups to the market. Natalie Harms/InnovationMap

A few years ago, the University of Houston renamed its Energy Research Park to the Technology Bridge. They wanted to create a program and workspace for companies inside the university to enter into the Houston innovation ecosystem. Turns out, the program also created a bridge for innovative companies entering the Houston market.

Two companies announced that they will open operations in the Technology Bridge — the first Houston offices for both, according to a news release.

Chemicals company Oleon is a subsidiary of France-based Avril, a financial and industrial company. Before the UH location, Oleon's only United States operation was a sales office in South Carolina. The other company is California-based Saratech, an engineering, software, services, and 3D printer sales company. Saratech has offices across the country, including an Austin office. The Houston office will focus on 3D printing.

According to Tom Campbell, executive director of the UH Office of Technology Transfer and Innovation, choosing a university to open a new office in a new market makes a lot of sense. There's a ready-made network of professors and students ripe with talent for internships and new and developing research.

Saratech's senior vice president, Rick Murphy, agrees that the new office can be mutually beneficial to UH and his company. Saratech already has a relationship similar to this with the University of California-Irvine.

"We are looking at universities to help with that, so industry can start educating their engineers to take advantage of this technology," Murphy says in the release.

Oleon also has previous relationships with universities in Europe and Asia. The company, which specializes in natural chemistry — specifically using fats and oils in various applications from cosmetics to automotive, plans on sustaining a lot of growth in Houston. The move represents the first of many instances of growth in the market.

"It is baby steps here, but the U.S. is a huge market," Dave Jacobs, general manager of operations for Oleon Americas, says in the release. "About 50 percent of the oil and gas market is here."

The Technology Bridge houses 23 startups and has 30,000 square feet of incubator space and over 700,000 square feet of space suited for laboratories, pilot-scale facilities, and light manufacturing. The bridge sits on the former Schlumberger campus just south of UH.

To Campbell, the bridge adds its own niche of research and lab space to the Houston innovation ecosystem as a whole, and both these companies' new offices are on par with the greater goals of the bridge.

"It's about economic development," Campbell says in the release. "A strong innovation economy is a rising tide that floats all boats."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”